NCT07645820
Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
Recruiting
Not specifiedAges 12–89ObservationalCastle Biosciences Incorporated
~450 participants
Updated 2026-06-12 on ClinicalTrials.gov
What's tested:Nevisense electrical impedance spectroscopy
At a glance
Recruiting sites
4 of 4 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Relationship between skin measurements and subsequent atopic dermatitis flares
Measured over Measurements taken over 90 days, 5 days a week
+1 more outcome measured
Conditions
Where it's being run
4 sites across 4 statesArizona1
Nevada1
New Hampshire1
Texas1
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Are 12 to 89 years old.
Have been diagnosed with atopic dermatitis (eczema).
Have had at least one atopic dermatitis flare within the past 2 months.
Are willing and able to use the Nevisense Go device at home, complete an electronic symptom diary, and attend study visits.
If currently using systemic treatment for atopic dermatitis, have been on the same treatment for at least 3 months and do not plan to change treatment during the study.
Exclusion
Are unwilling or unable to avoid applying creams, lotions, ointments, or soap to measurement areas for 6 hours before measurements.
Do not have suitable skin areas for study measurements.
Have another skin condition that may affect study assessments.
Are pregnant.
What this trial measures
- Relationship between skin measurements and subsequent atopic dermatitis flaresMeasurements taken over 90 days, 5 days a week
Electrical Impedance Spectroscopy (EIS) measurements collected over time to assess their relationship to subsequent participant-reported atopic dermatitis flares occurring before visible signs or symptoms are apparent.
- Develop and validate an algorithm using Nevisense Go EISFrom enrollment until end of treatment at 90 days.
To develop and validate an algorithm using Nevisense Go EIS data that can calculate the momentary likelihood of AD flares, before signs or symptoms